Long-term outcomes of ruxolitinib (RUX) therapy in patients (pts) with myelofibrosis (MF): 5-year update from COMFORT-I.

被引：0
|
作者：
Gupta, Vikas
Verstovsek, Srdan
Mesa, Ruben A.
Gotlib, Jason R.
DiPersio, John F.
Catalano, John V.
Deininger, Michael W. N.
Miller, Carole Brennan
Silver, Richard T.
Talpaz, Moshe
Winton, Elliott F.
Harvey, Jimmie Huling
Arcasoy, Murat.
Hexner, Elizabeth O.
Lyons, Roger M.
Paquette, Ronald
Raza, Azra
Kornacki, Deanna
Sun, Kang
Kantarjian, Hagop M.
机构：
[1] Univ Toronto, Princess Margaret Hosp, Toronto, ON, Canada
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Mayo Clin, Scottsdale, AZ USA
[4] Stanford Univ, Sch Med, Stanford Canc Ctr, Stanford, CA 94305 USA
[5] Washington Univ, Sch Med, St Louis, MO 63110 USA
[6] Frankston Hosp, Frankston, Australia
[7] Dept Clin Haematol, Frankston, Australia
[8] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[9] St Agnes Canc Inst, Baltimore, MD USA
[10] Weill Cornell Med Ctr, New York, NY USA
[11] Univ Michigan, Ann Arbor, MI 48109 USA
[12] Emory Univ, Sch Med, Atlanta, GA 30322 USA
[13] Birmingham Hematol Oncol Associates, Birmingham, AL USA
[14] Duke Univ, Hlth Syst, Durham, NC USA
[15] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
[16] Canc Care Ctr South Texas, US Oncol, San Antonio, TX USA
[17] Univ Calif Los Angeles, Ronald Reagan UCLA Med Ctr, Los Angeles, CA USA
[18] Columbia Univ, Med Ctr, New York, NY USA
[19] Incyte Corp, Wilmington, DE USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.7012
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7012
引用
收藏
页数：4
相关论文
共 50 条
  • [31] Long-Term Outcome of Ruxolitinib Treatment in Patients with Myelofibrosis: Durable Reductions in Spleen Volume, Improvements in Quality of Life, and Overall Survival Advantage in COMFORT-I
    Verstovsek, Srdan
    Mesa, Ruben A.
    Gotlib, Jason
    Levy, Richard S.
    Gupta, Vikas
    DiPersio, John F.
    Catalano, John V.
    Deininger, Michael W. N.
    Miller, Carole B.
    Silver, Richard T.
    Talpaz, Moshe
    Winton, Elliott F.
    Harvey, Jimmie H., Jr.
    Arcasoy, Murat O.
    Hexner, Elizabeth O.
    Lyons, Roger M.
    Paquette, Ronald
    Raza, Azra
    Vaddi, Kris
    Erickson-Viitanen, Susan
    Sun, William
    Sandor, Victor A.
    Kantarjian, Hagop M.
    BLOOD, 2012, 120 (21)
  • [32] Actual 5-Year Long-term Nutritional Outcomes After Curative Gastrectomy in Gastric Cancer Patients
    Park, D.
    Kim, K.
    Park, D.
    Park, Y.
    Ahn, S.
    Kim, H.
    ANNALS OF SURGICAL ONCOLOGY, 2016, 23 : S177 - S177
  • [33] Long-Term Efficacy and Safety (5 Years) in RESPONSE, a Phase 3 Study Comparing Ruxolitinib (rux) with Best Available Therapy (BAT) in Hydroxyurea (HU)-Resistant/Intolerant Patients (pts) with Polycythemia Vera (PV)
    Kiladjian, Jean-Jacques
    Zachee, Pierre
    Hino, Masayuki
    Pane, Fabrizio
    Masszi, Tamas
    Harrison, Claire N.
    Mesa, Ruben A.
    Miller, Carole B.
    Passamonti, Francesco
    Durrant, Simon
    Griesshammer, Martin
    Kirito, Keita
    Besses, Carles
    Moiraghi, Beatriz
    Rumi, Elisa
    Rosti, Vittorio
    Blau, Igor W.
    Francillard, Nathalie
    Dong, Tuochuan
    Wroclawska, Monika
    Vannucchi, Alessandro M.
    Verstovsek, Srdan
    BLOOD, 2018, 132
  • [34] The Effect of Facial Burns on Long-Term Outcomes in Young Adults: A 5-Year Study
    Ryan, Colleen M.
    Lee, Austin
    Stoddard, Frederick J., Jr.
    Li, Nien Chen
    Schneider, Jeffrey C.
    Shapiro, Gabriel D.
    Griggs, Cornelia L.
    Wang, Chao
    Palmieri, Tina
    Meyer, Walter J.
    Pidcock, Frank S.
    Reilly, Debra
    Sheridan, Robert L.
    Kazis, Lewis E.
    Tompkins, Ronald G.
    JOURNAL OF BURN CARE & RESEARCH, 2018, 39 (04): : 497 - 506
  • [35] Assessing the Long-Term Outcomes of Minor Lower Limb Amputations: A 5-Year Study
    Uzzaman, Mohammed Mohsin
    Jukaku, Saud
    Kambal, Amir
    Hussain, Syed Tahir
    ANGIOLOGY, 2011, 62 (05) : 365 - 371
  • [36] ENESTnd 5-year (y) update: Long-term outcomes of patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with frontline nilotinib (NIL) versus imatinib (IM).
    Larson, Richard A.
    Kim, Dong-Wook
    Jootar, Saengsuree
    Pasquini, Ricardo
    Clark, Richard E.
    Lobo, Clarisse
    Goldberg, Stuart L.
    Shibayama, Hirohiko
    Hochhaus, Andreas
    Saglio, Giuseppe
    Kantarjian, Hagop M.
    Kemp, Charisse
    Deng, Weiping
    Menssen, Hans D.
    Hughes, Timothy P.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [37] Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis (vol 30, pg 1701, 2016)
    Harrison, C. N.
    Vannucchi, A. M.
    Kiladjian, J-J
    Al-Ali, H. K.
    Gisslinger, H.
    Knoops, L.
    Cervantes, F.
    Jones, M. M.
    Sun, K.
    McQuitty, M.
    Stalbovskaya, V.
    Gopalakrishna, P.
    Barbui, T.
    LEUKEMIA, 2017, 31 (03) : 775 - 775
  • [38] Long-Term Safety and Efficacy of Deferasirox (DFX) in Pediatric Patients (PTS) with Transfusional Hemosiderosis: Results From A 5-Year (Y) Observational Study (ENTRUST)
    Vichinsky, E.
    El Beshlawy, A.
    Alzoebie, A.
    Kamdem, A.
    Koussa, S.
    Chotsampancharoen, T.
    Bruederle, A.
    Gilotti, G.
    Han, J.
    Elalfy, M.
    ANESTHESIA AND ANALGESIA, 2016, 123 : 6 - 7
  • [39] Lessons from the 5-Year Experience of Japanese Long-term Care Insurance
    Jeong, Hyoung-Sun
    JOURNAL OF THE KOREAN MEDICAL ASSOCIATION, 2005, 48 (11): : 1054 - 1060
  • [40] 5-YEAR OUTCOMES BY DONOR TYPE FROM THE LONG-TERM EXTENSION OF THE BELATACEPT BENEFIT-EXT STUDY
    Muehlbacher, Ferdinand
    Florman, Sander
    Zhang, Rubin
    Lang, Philippe
    Lehner, Frank
    Massari, Pablo
    Garcia, Valter D.
    Pupim, Lara
    Durrbach, Antoine
    TRANSPLANT INTERNATIONAL, 2013, 26 : 92 - 92
12345